Gauruv Bose

Gauruv Bose

Auto-generated profile, based on publicly available information

Gauruv Bose

Brigham and Women's Hospital

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 August 2010 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Closed access
PDF file
PEP. M. G. Erkens
P. M. G. Erkens
EGE. Gandara
E. Gandara
PWP. Wells
P. Wells
ASA. Y.-H. Shen
A. Y.-H. Shen
GBG. Bose
G. Bose
MCM. Carrier
M. Carrier

10 February 2021 in Multiple Sclerosis Journal
Verified
Journal Article
Open access
PDF file
STSimon Thebault
Simon Thebault
GBGauruv Bose
Gauruv Bose
RBRonald Booth
Ronald Booth
MFMark S. Freedman
Mark S. Freedman
A simple blood-derived biomarker is desirable in the routine management of multiple sclerosis (MS) patients and serum neurofilament light chain (sNfL) is the most promising candidate. Although its utility was first shown in cerebrospinal fluid (CSF), technological advancements have enabled reliable detection in serum and less frequently plasma, obviating the need for repeated lumbar punctures. In this review, after defining the knowledge gap in MS management that many hope sNfL could fill, we summarize salient studies demonstrating associations of sNfL levels with outcomes of interest. We group these outcomes into inflammatory activity, progression, treatment response, and prediction/prognosis. Where possible we focus on data from real-world perspective observational cohorts. While acknowledging the limitations of sNfL and highlighting key areas for ongoing work, we conclude with our opinion of the role for sNfL as an objective, convenient, and cost-effective adjunct to clinical assessment. Paving the way for other promising biomarkers both blood-derived and otherwise, sNfL is an incremental step toward precision medicine for MS patients.

16 February 2021 in BMJ Open
Verified
Journal Article
Open access
PDF file
GBGauruv Bose
Gauruv Bose
JGJustin Graveline
Justin Graveline
VYVignan Yogendrakumar
Vignan Yogendrakumar
RSRisa Shorr
Risa Shorr
DFDean A Fergusson
Dean A Fergusson
DDDar Dowlatshahi
Dar Dowlatshahi
Objectives Current guidelines do not recommend direct oral anticoagulants (DOACs) to treat cerebral venous thrombosis (CVT) despite their benefits over standard therapy. We performed a systematic review to summarise the published experience of DOAC therapy in CVT. Data sources MEDLINE, Embase and COCHRANE databases up to 18 November 2020. Eligibility criteria All published articles of patients with CVT treated with DOAC were included. Studies without follow-up information were excluded. Data extraction and synthesis Two independent reviewers screened articles and extracted data. A risk of bias analysis was performed. Primary and secondary outcome measures Safety data included mortality, intracranial haemorrhage (ICH) or other adverse events. Efficacy data included recurrent CVT, recanalisation rates and disability by modified Rankin Scales (mRS). Results 33 studies met inclusion criteria. One randomised controlled trial, 5 observational cohorts and 27 case series or studies reported 279 patients treated with DOAC for CVT: 41% dabigatran, 47% rivaroxaban, 10% apixaban and 2% edoxaban, in addition to 315 patients treated with standard therapy. The observational cohorts showed a similar risk of death in DOAC and standard therapy arms (RR 2.12, 95% CI 0.29 to 15.59). New ICH was reported in 2 (0.7%) DOAC-treated patients and recurrent CVT occurred in 4 (1.5%). A favourable mRS between 0 and 2 was reported in 94% of DOAC-treated patients, more likely than standard therapy in observational cohorts (RR 1.13, 95% CI 1.02 to 1.25). Conclusion The evidence for DOAC use in CVT is limited although suggests sufficient safety and efficacy despite variability in timing and dose of treatment. This systematic review highlights that further rigorous trials are needed to validate these findings and to determine optimal treatment regimens.

4 May 2022 in Annals of Neurology
Verified
Journal Article
Closed access
GBGauruv Bose
Gauruv Bose
BHBrian C. Healy
Brian C. Healy
HLHrishikesh A. Lokhande
Hrishikesh A. Lokhande
Marinos SotiropoulosMarinos Sotiropoulos
Marinos Sotiropoulos
MPMariann Polgar‐Turcsanyi
Mariann Polgar‐Turcsanyi
TCTanuja Chitnis
Tanuja Chitnis

1 June 2012 in Thrombosis Research
Verified
Journal Article
Closed access
PEPetra M.G. Erkens
Petra M.G. Erkens
EGEsteban Gandara
Esteban Gandara
PWPhilip S. Wells
Philip S. Wells
ASAlex Yi-Hao Shen
Alex Yi-Hao Shen
GBGauruv Bose
Gauruv Bose
MCMarc Carrier
Marc Carrier

1 July 2021 in Multiple Sclerosis and Related Disorders
Verified
Journal Article
Closed access
GBGauruv Bose
Gauruv Bose
CRCarolina Rush
Carolina Rush
HAHarold Atkins
Harold Atkins
MFMark S. Freedman
Mark S. Freedman